Rituxan Side Effects Could Result In Brain Disease Lawsuits
Rituxan May Cause Brain Disease. On December 19, 2006 Genentech issued a warning to healthcare providers for their oncology drug Rituxan, advising them that the drug has been linked to the deaths of two lupus patients from a rare brain disease, called Progressive multifocal leukoencephalopathy (PML). On November 10, 2006, Health … [Read more...]
Raptiva PML Side Effects Lawsuit
Raptiva PML Side Effect Lawsuits. Raptiva, a drug used to treat psoriasis, has been associated with a serious viral brain disease called progressive multifocal leukoencephalopathy (Progressive Multifocal Leukoencephalopathy PML). Progressive Multifocal Leukoencephalopathy PML is a rare virus that affects the central nervous system … [Read more...]
Progressive Multifocal Leukoencephalopathy Brain Infection
Gilenya May Cause Brain Infection. Our firm is investigating potential lawsuits on behalf of Gilenya users who developed progressive multifocal leukoencephalopathy (PML), a rare but serious brain infection. The U.S. Food and Drug Administration (FDA) reported cases of PML among Gilenya users in 2013, and again in August 2015. The … [Read more...]
PML Disease Injury Lawsuits
Drugs Have Been Found To Cause PML. Progressive Multifocal Leukoencephalopathy (PML) is an irregular disorder of the nervous system that mainly affects individuals with suppressed immune systems (including, allograft recipients such as kidney transplant patients; patients with cancers such as leukemia or lymphoma; and approximately … [Read more...]
Health Canada Strengthens Safety Warnings for Multiple Sclerosis Drug Gilenya
Health Canada, Canada’s health regulatory agency, has updated the label information for the multiple sclerosis drug Gilenya (fingolimod) to include stronger safety warnings on the risk of skin cancer and the rare brain infection progressive multifocal leukoencephalopathy (PML), which can be fatal. Gilenya, a prescription drug, is … [Read more...]
Tecfidera Linked to Case of PML Brain Infection
Tecfidera And Its Serious Side Effects. The multiple sclerosis drug Tecfidera has been linked to a case of a serous brain infection called progressive multifocal leukoencephalopathy (PML), the U.S. Food and Drug Administration (FDA) warned on November 25th. According to the agency's Drug Safety Communication, a patient taking … [Read more...]
Tysabri PML Risk Increases With Use
Tysabri PML Risk Increases. Tysabri, a popular treatment for relapsing multiple sclerosis (MS), is more likely to cause a serious brain infection called progressive multifocal leukoencephalopathy, or PML, the longer it is used, according to the U.S. Food & Drug Administration (FDA). The agency announced Friday that the Tysabri … [Read more...]
Biogen Idec Restarts Tysabri Updates
Biogen Restarts Tysabri Update. The maker of Tysabri will once again provide monthly updates regarding new cases of progressive multifocal leukoencephalopathy, or PML, an often fatal brain infection seen in some people treated with the multiple sclerosis (MS) drug. Biogen Idec Inc. had stopped providing the monthly PML updates last … [Read more...]
Tysabri Scrutiny Over Brain Infection
Tysabri May Cause Brain Infection. European regulators are taking another look at Tysabri. According to The Wall Street Journal, the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) is concerned that Tysabri may have a higher rate of a rare brain infection called progressive multifocal … [Read more...]
Third Rituxan Patient Diagnosed with PML
Rituxan Patient Diagnosed with PML A third Rituxan patient has developed a serious and often fatal brain infection called progressive multifocal leukoencephalopathy (PML). According to a statement posted on the Food & Drug Administration (FDA) Web site, this is the first case of PML in a patient with rheumatoid arthritis treated … [Read more...]
Tysabri-PML Link Will Weigh on Biogen Stock
Tysabri-PML Link Drag Biogen Stock. Tysabri troubles could continue to cause a drag on Biogen Idec stock, according to a Wall Street Journal report. A recently released research note from Barclays Capital indicated use of Tysabri is being tempered by worries over how many patients may develop progressive multifocal … [Read more...]
Tysabri Safety Info Includes PML Cases
Tysabri Safety Info. The Food & Drug Administration (FDA) is updating Tysabri safety information to include cases of progressive multifocal leukoencephalopathy or PML, a rare brain infection that some Tysabri patients have developed. However, according to The Wall Street Journal, the agency is not making any changes to the … [Read more...]
Brain Infection in More Tysabri Patients
Tysabri Patients Brain Infection Reported. Two more Tysabri patients have developed progressive multifocal leukoencephalopathy or PML. Both new cases occurred in European patients, according to a Wall Street Journal report. Tysabri was taken off the market in 2005 in the U.S. after three patients in clinical trials developed PML. … [Read more...]
10th Tysabri Patient Stricken with PML
Tysabri Patient Stricken with PML. Another Tysabri patient has developed progressive multifocal leukoencephalopathy or PML. This brings the total number of cases of the brain infection linked to Tysabri since it was reintroduced to market to 10. Of those patients, at least 3 have died. According to a report in the Boston Business … [Read more...]
Rituxan – PML Link Could Spark FDA Action
Regulators Are Taking a Look At The Link Between Rituxan And PML. U.S. health regulators are taking a look at the lymphoma drug Rituxan because of its possible association with progressive multifocal leukoencephalitis (PML), an often fatal brain infection. According to The Wall Street Journal, the Food & Drug Administration … [Read more...]
Study Finds 57 Rituxan Patients Developed PML
Patients Taking Rituxan May Be At Risk. Patients taking Rituxan may be at risk of developing a serious, and often fatal brain infection called progressive multifocal leukoencephalitis (PML), according to the findings of a new study. The study, published in the journal Blood, reports on 57 cases of PML that developed in patients … [Read more...]
Raptiva Pulled from Market Following Deaths
Raptiva Pulled from U.S. Market. Raptiva, an injectable drug used to treat moderate to severe plaque psoriasis, is being withdrawn from the U.S. market. According to Genentech, Raptiva has been associated with progressive multifocal leukoencephalopathy (PML), a serious and almost always fatal brain infection caused by a … [Read more...]
Tysabri Linked to Another Case of PML
Tysabri Linked to PML. Another Tysabri patient has developed progressive multifocal leukoencephalopathy (PML), an often fatal brain disease. Just three months ago, Biogen Idec said two additional patients had contracted PML. PML attacks the brain and central nervous system and is usually fatal. It is caused by a polyomavirus, … [Read more...]
CellCept Label Changed to Reflect Risk of PML
Part of a class of drugs called immunosuppressants and was approved in 1995. The maker of CellCept,Swiss Drug Maker Roche, has informed healthcare providers that it has modified the "Warnings" and "Adverse Reactions" sections of the to include information on its association with several cases of Progressive Multifocal … [Read more...]
Off-Label Use of Rituxan Linked to Fatal Leukoencephalopathy
FDA is Warning Healthcare Professionals Regarding the Risk for PML Patients Receiving Rituxan. The US Food and Drug Administration (FDA) is warning healthcare professionals regarding the risk for progressive multifocal leukoencephalopathy (PML) in patients receiving rituximab intravenous infusion (Rituxan, made by Genentech, Inc, and … [Read more...]
Life-threatening Brain Infection in Patients with Systemic Lupus Erythematosus
Brain Infection Have Been Reported In Patients Who Were Treated with Rituxan. FDA has received reports of the death of two patients who were treated with Rituxan for systemic lupus erythematosus (SLE). Both patients developed a life-threatening viral infection of the brain. This infection is called progressive multifocal … [Read more...]
TYSABRI: THE DRUG THAT REFUSES TO DIE
TYSABRI Linked To Fatal Brain Disease. Despite the fact that Tysabri has been linked to five cases of a rare and often fatal brain disease, its manufacturers (Elan Corp. PLC of Ireland and Biogen Idec Inc. of Massachusetts) are simply unwilling to give up their quest to bring the drug to market and keep it … [Read more...]
